Creative Biolabs Launched a Brand New Bioconjugation Service

With Ph.D. level scientists and over a decade of experience in recombinant antibody production, antibody engineering, and synthetic chemistry, Creative Biolabs recently launched a brand new bioconjugation service to help create highly customized ADCs.

What is ADC? Consisting of the monoclonal antibody, a cytotoxic payload, and a molecular linker, antibody-drug conjugates (ADCs) inherit such superiorities and more remarkably, expand the therapeutic window of the conjugated drugs (payloads), which are usually highly toxic and diverse in their biochemical nature.

“A successful ADC should be chemically and physiologically stable in blood stream, exert similar antigen binding pattern compared with the unconjugated antibody, and exhibit desired payload toxicological effects once internalized. Like travelling to a destination on a highway, our ADC development services extends from the starting point—antibody identification, to the final destination—creation and evaluation of the ADC, every step of the way,” said Dr. Monika Müller, Scientific Officer of Creative Biolabs.

“It is an elaborate designing process that involves careful planning, meticulous execution, and intensive trouble-shooting. An effective combination of the most suitable components will greatly increase the chance for a successful ADC. With this concept in mind, we has perfected our ADC development services, and we divide our services into six independent yet interconnected modules, just like the relationship between each component in an ADC.”

Monoclonal antibody-based immunotherapies against cancer and other infectious diseases are highly advantageous comparing to conventional therapeutic approaches due to their high specificity and affinity towards well-defined targets. Creative Biolabs is dedicated to serve the unique needs of our clients in ADC development projects by providing customized services that are tailored to meet your R&D timeline and budget.

About Creative Biolabs

Established in 2004, Creative Biolabs is highly specialized in advanced antibody biochemistry and engineering. With more than a decade of exploration and expansion, our current research and service capacity covers the entire new drug discovery and development pipeline, ranging from early discovery, preclinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, we have established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world. 

Media Contact
Company Name: Creative Biolabs
Contact Person: Bella Smith
Email: marketing@creative-biolabs.com
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: http://www.creative-biolabs.com